CBA/CaH

CBA/CaH

CBA/CaH

Strain details
Nomenclature CBA/CaHOzarc
Common nameCBA/CaH
SynonymsCBA
StrainInbred
Coat colourAgouti (A/A)
SpeciesMouse
LocationArea Oz2
Weekly wean target20 males, 20 females

Strain description

  • MHC haplotype: H2Kk
  • Complement Factor: C5 normal
  • CBA/CaH for its low activity and docile behaviour.
  • This strain has high overall tumour incidence, which includes hepatomas and mammary tumours. Often used in cancer research to study tumorigenesis and tumour progression.
  • CBA/CaH mice are resistant to the induction of atherosclerosis by a high-fat diet, making them suitable for studying cardiovascular diseases and lipid metabolism.
  • There is considerable variation between different sublines of CBA/CaH mice, and care must be taken when comparing data from different sublines.
  • CBA/CaH mice also exhibit a high rate of spontaneous mutations, which may impact experimental outcomes and require careful genetic monitoring.
  • Originally developed by Strong (1920) from Bagg albino x DBA. Offspring split into a low mammary tumour incidence strain (CBA) and a high incidence strain (C3H). Strong to Andervont in 1947. Andervont to The Jackson Laboratory in 1948.Circa 1953 to the MRC Mammalian Genetics Unit, Harwell, hence the H in the nomenclature.
  • Received at ARC from CULAS (1997).
  • Received at Ozgene ARC from ARC (2023).
  • CBA/CaH strain is widely distributed and commonly used as a general-purpose strain in research due to its ease of handling and availability.
  • This strain of mice is a valuable research tool for studying cancer, cardiovascular diseases, and other areas of biomedical research.

Past ARC and transfer reports:

Current Ozgene ARC reports (from 01-Jun-2023)

  • Mouse images are representative only. Actual phenotypes may vary based on genotype, sex, age, husbandry, health status, and other factors.